In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Policy & Regulation

Regulatory developments from the EU and the US are having widely felt effects on companies operating globally in both medtech and biopharma. The patents and pricing battle has engulfed the FDA and USPTO, while the impact of MDR and IVD regulation changes can be felt keenly for those in working in Europe.

Medicare Price Setting And The Value Of Post-Approval R&D Spending

Will scrutiny by the Centers for Medicare and Medicaid Services eventually lead to shifts in investment away from improving older drugs toward developing new products? 

Will Medicare Price Negotiation Stop Post-Approval R&D?

Infographic: One of the more prominent arguments against the Medicare drug price negotiation program is that by limiting the number of years that products can be marketed before price caps are imposed, the scheme discourages development of additional indications.

Innovation Adoption: ‘Medtech’s Ongoing Challenge Of The Day’

UK ministers are increasingly focusing on the need to improve uptake of new technologies in the National Health Service. Ambitious programs have been launched but implementing them effectively for lasting change in a delivery system under acute stress is a challenge of a different order.

Splits Over Data Protection Could Hamper EU Pharma Revision

The chances of reaching agreement on proposals to overhaul the EU pharma rules before the European Parliament elections in June 2024 are receding as disagreements emerge over key issues such as regulatory data protection and how to encourage antimicrobial R&D.

Outlook 2024 e-Book

Outlook 2024 cover

Download a PDF copy of the Outlook 2024 collection, including Scrip 100 league tables.